Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device - Trial NCT06254664
Access comprehensive clinical trial information for NCT06254664 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xiromed LLC and is currently Completed. The study focuses on COPD. Target enrollment is 116 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xiromed LLC
Timeline & Enrollment
Phase 1
Oct 03, 2022
Oct 27, 2023
Primary Outcome
In vitro Measurement of Emitted Dose
Summary
An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug
 Inhalation Powder, Hard Capsule, Inhaler Device. Zephir inhaler robustness will be assessed
 by in vitro testing of the Zephir inhaler after 12 weeks of patient use
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06254664
Non-Device Trial